Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV (Enduring)

Gastroenterology
Curriculum:
Strategies for Safe and Efficacious Use of New and Emerging Therapies in HCV
Credits:
1 AMA PRA Category 1 Credit(s)™
Launch Date:
November 03, 2015
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Gastroenterologists, hepatologists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with HCV.

Relevant Terms:

HCV; drug-drug interactions; interferon-free regimens; HIV/HCV coinfection

Ira Jacobson, MD

Ira Jacobson, MD
Chairman, Department of Medicine
Mount Sinai Beth Israel Medical Center
Vice Chair of Medicine
Mount Sinai Health Care System
Senior Faculty, Icahn School of Medicine at Mount Sinai
New York, NY

Ira M. Jacobson, MD, earned his bachelor of science summa cum laude from Yale University in New Haven, Connecticut, and his MD from Columbia University College of Physicians and Surgeons in New York City. After completing an internship and residency at the University of California, San Francisco, he trained as a fellow in gastroenterology and hepatology at Massachusetts General Hospital and Harvard Medical School. In 1984, he joined the faculty at Weill Cornell Medical College and New York Presbyterian Hospital in New York City. Dr. Jacobson has served as chief of the Division of Gastroenterology and Hepatology, Vincent Astor Distinguished Professor of Medicine, and medical director of the Center for the Study of Hepatitis C. In March 2015, he assumed the position of chair of medicine at Mount Sinai Beth Israel Medical Center, vice chair of medicine, and co-director of the Liver Institute at the Icahn School of Medicine at Mount Sinai in New York City.
 
Dr. Jacobson is a fellow of the American College of Physicians, American College of Gastroenterology, and American Gastroenterological Association, and he is a member of the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. He has been an investigator in many trials on antiviral therapy for hepatitis B and C. He has been lead principal investigator and author of a number of trials. He has served on the Gastroenterology and Transplant Hepatology Boards of the American Board of Internal Medicine, as associate editor of the Journal of Hepatology, and as a reviewer for several other journals. He has authored or co-authored more than 250 peer-reviewed papers, chapters and reviews, including papers in New England Journal of Medicine, Lancet, Gastroenterology, Hepatology, Journal of Hepatology, Journal of Viral Hepatitis, and Clinical Gastroenterology and Hepatology. He has edited 2 books on endoscopic retrograde cholangiopancreatography and a volume on hepatitis B for Clinics in Liver Disease. He co-chairs the annual Viral Hepatitis Congress in Frankfurt, Germany. Dr. Jacobson was recently named co-chief medical editor of HCV Next, a new publication from Slack Incorporated that also appears on Healio.com/HCV.

Nancy Reau, MD, FAASLD, AGAF

Nancy Reau, MD, FAASLD, AGAF
Associate Professor of Medicine
Section Chief, Hepatology
Associate Director of Solid Organ Transplantation
Rush University Medical Center
Chicago, IL

Nancy Reau, MD, FAASLD, AGAF, is currently associate director of solid organ transplantation and section chief of hepatology at Rush University Medical Center in Chicago, Illinois. She received her bachelor of arts degree at Oberlin College in Oberlin Ohio, and her doctorate of medicine, cum laude, from the Ohio State University in Columbus, Ohio. She completed a medicine residency and a gastroenterology fellowship at the Ohio State University, and an advanced transplant hepatology fellowship at The Johns Hopkins Medical Center in Baltimore, Maryland.
 
Dr. Reau was employed at Rush University Medical Center in Chicago as an assistant professor from 2002 until 2005 before accepting a position at the University of Chicago Medicine. She became an associate professor of medicine in 2010, medical director of hepatology clinical and translational research in 2015, and then joined Rush University Medical Center in 2015. She is a fellow of the American Gastroenterological Association and the American Association for the Study of Liver Diseases (AASLD). She has also been the annual honoree of the Illinois chapter of the American Liver Foundation.
 
Dr. Reau’s research interest is in viral hepatitis, both in drug development as well as utilization. She has authored or co-authored more than 100 peer-reviewed articles, invited reviews, editorials, and on-line programs, as well as several book chapters, and 2 books. She is on the editorial board for Hepatology and is a guest editor for Clinical Liver Disease for the topic of hepatitis C. She served, as the chair of the public policy committee for the AASLD, was a member of the AASLD practice guideline committee, and a member of the American College of Gastroenterology (ACG) women’s committee. She has been a member of the national board of directors of the American Liver Foundation (ALF) and served as the president of the Illinois chapter of the ALF, a member of the board of directors, and a member of the medical advisory committee (MAC). She is currently co-chair of the National ALF MAC and on multiple advisory boards including Medscape and Medivo. She is a member of the steering committee for the hepatitis C special interest group (SIG) for the AASLD and a member of the ACG training committee. Effective 2013, she is member of the AASLD/IDSA Practice Guidelines for Hepatitis C. 
1. Discuss the importance of HCV treatment and achievement of sustained viral response for improvement of hepatic and extrahepatic manifestations in mild as well as severe disease.
2. Apply the clinical evidence to optimize treatment duration, monitoring strategies, and drug-drug interactions for newly approved and emerging interferon-free regimens.
3. Appraise the clinical evidence to determine how to optimize the use of newly approved and emerging interferon-free regimens in special populations of patients including those with decompensated cirrhosis, HIV/HCV coinfection, transplant/post-transplant of liver, renal impairment, and HCV genotype 3.

Provided by Vindico Medical Education  

Release Date: November 3, 2015
Expiration Date: November 3, 2016
 
Physician Continuing Medical Education 
 
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Type of Activity 
Knowledge and Performance

Target Audience 
The intended audience for this activity is gastroenterologists, hepatologists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with HCV.

Educational Support 
This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

Disclosure of Conflicts of Interest
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
 
Faculty 
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Ira Jacobson, MD has received Consulting Fees: AbbVie, Achillion, Bristol-Myers Squibb, Enanta, Gilead, Janssen, Merck
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Gilead, Janssen
Contracted Research: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, Tobira

Nancy Reau, MD, FAASLD, AGAF has received Consulting Fees: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Salix.
Contracted Research: AbbVie, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Merck.
 
External Reviewers
Joseph K. Lim, MD has received Consulting Fees: Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Merck.
Contracted Research: Abbott, Bristol-Myers Squibb, Gilead, Hologic, Janssen.
 
Ronald A. Codario, MD, FACP, FNLA, CCMEP has no relevant financial relationship to disclose.
 
Planners 
Vindico Medical Education Staff: No relevant financial relationships to disclose.
 
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance. 
 
Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
 
Media 
Internet 
 
Disclaimer
The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Method of Participation and Request for Credit 
To participate in this CME activity, you must complete the activity in its entirety and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
 
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1   
** Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
 
** If you are experiencing video playback issues with Google Chrome, please refer to a support article by clicking here
 
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 7.0 or above